On Oct 28, major Wall Street analysts update their ratings for $Avantor (AVTR.US)$, with price targets ranging from $25 to $28.
Morgan Stanley analyst Tejas Savant maintains with a buy rating, and adjusts the target price from $28 to $27.
Barclays analyst Luke Sergott maintains with a buy rating, and maintains the target price at $25.
Wells Fargo analyst Brandon Couillard maintains with a buy rating, and adjusts the target price from $30 to $28.
Baird analyst Catherine Ramsey Schulte maintains with a buy rating, and maintains the target price at $26.
Stifel analyst Daniel Arias maintains with a buy rating, and maintains the target price at $28.
Furthermore, according to the comprehensive report, the opinions of $Avantor (AVTR.US)$'s main analysts recently are as follows:
Avantor experienced a return to growth in LSS and Bioprocessing recovery, which was balanced out by weakness in U.S. semiconductor performance, according to an analysis shared with investors following the company's earnings release.
The firm expressed satisfaction with Avantor's robust free cash flow generation during the quarter and the gradual uptick in bioprocessing and equipment & instrumentation revenue, which surpassed expectations. Although management has not offered projections for 2025, the expectation is for a consistent, gradual enhancement throughout the fiscal year.
The softness in the semiconductor segment is overshadowing what is otherwise considered a 'solid' revenue outcome. Attention remains fixated on the EBITDA margin shortfall, casting doubts on the prospect of achieving a 20% EBITDA margin by the year 2025. It is anticipated that the company will approach this target, but it will necessitate a favorable product mix and additional cost reductions to attain it. Expectations for growth have been moderated to 3%, taking into account the semiconductor situation and margin outlook for 2025.
The firm indicated that Avantor's third quarter performance surpassed expectations, despite a notable weakness in the Semiconductor segment. The Bioprocess area showed strong results, while the Laboratory division experienced a modest improvement alongside robust cost management and Free Cash Flow generation.
Avantor's $12M revenue shortfall, primarily due to decreased sales in applied markets, was somewhat mitigated by stronger results in Lab Solutions and bioprocessing segments. Despite the revenue miss, there's a positive outlook on the stock's performance during downturns and confidence in the company's ability to meet its FY25 financial targets.
Here are the latest investment ratings and price targets for $Avantor (AVTR.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月28日，多家华尔街大行更新了$Avantor (AVTR.US)$的评级，目标价介于25美元至28美元。
摩根士丹利分析师Tejas Savant维持买入评级，并将目标价从28美元下调至27美元。
巴克莱银行分析师Luke Sergott维持买入评级，维持目标价25美元。
富国集团分析师Brandon Couillard维持买入评级，并将目标价从30美元下调至28美元。
贝雅分析师Catherine Ramsey Schulte维持买入评级，维持目标价26美元。
斯迪富分析师Daniel Arias维持买入评级，维持目标价28美元。
此外，综合报道，$Avantor (AVTR.US)$近期主要分析师观点如下：
avantor在LSS和生物加工复苏方面经历了增长，但美国半导体业绩不佳，根据一份与投资者分享的分析，这些成绩使公司在营业收入发布后的收益中保持平衡。
公司对avantor在本季度稳健的自由现金流产生和生物加工、设备和仪器营业收入逐渐上升表示满意，这超出了预期。尽管管理层未对2025年提供预测，但预期在财政年度中整体、逐步增强。
半导体领域的疲软状态掩盖了除此之外被认为是‘稳健’的营业收入结果。关注点仍然集中在EBITDA利润率不足上，对于2025年实现20%的EBITDA利润率的前景产生了质疑。预计公司会朝着这个目标努力，但需要有利的产品组合和额外的成本降低才能实现。增长预期已经调整为3%，考虑到半导体局势和2025年利润预期。
公司表示avantor第三季度的表现超出了预期，尽管半导体领域存在明显的疲软。生物加工领域表现强劲，而实验室部门除了强劲的成本管理和自由现金流产生外还经历了适度改善。
avantor由于应用市场销售减少导致1200万美元的营业收入缺口，但实验室解决方案和生物加工领域的成绩更强劲，对股票在低迷时期的表现持积极态度，对公司实现2025财务目标的信心不减。
以下为今日5位分析师对$Avantor (AVTR.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
